tirzepatide fda submission confirms shortage is still over, gives compounders a grace period FDA Approves Zepbound (tirzepatide) for

It is one of the most watched assets in the GLP-1 pipeline because it may push efficacy beyond current injectable therapies

An important question to ask, and one we may never have a clear answer to, is what amount of residual gastric contents increases the risk of aspiration? Surely, type of gastric contents (liquid or solid) also matters

But there is far more to health than your weight. Its vital to recognise obesity as the complex multifactorial disease that it is, says Dr Stanford

Our ability to produce and maintain a high level of glutathione in our bodies is critical to recovering from chronic illnesses

In the SURPASS clinical trial program, post-hoc analyses revealed decreases in hsCRP levels among tirzepatide-treated participants compared to baseline